POM-V Prescription Required

Rhiniseng Suspension for Injection for Pigs

Active ingredients: Bordetella bronchiseptica, Pasteurella multocida

Form

Injection

Species

Pigs

Manufacturer

Laboratorios Hipra SA

VMD MA No.

17533/5009

What it's used for

For active immunisation of dogs against to reduce clinical signs of upper respiratory tract disease and bacterial shedding post infection. Onset of immunit...

Full indications, dosage and side effects ↓

View official SPC (PDF)

The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.

Paying less for Bordetella bronchiseptica +...

1

Ask your vet for a written prescription

They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.
2

Fill it at a registered online retailer

The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.

Your prescription rights → VMD register of retailers →

Prescription required

Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.

Clinical information

Rhiniseng Suspension for Injection for Pigs — SPC Details

Source: VMD Summary of Product Characteristics (SPC). Last updated 27 Mar 2026.

For active immunisation of dogs against to reduce clinical
signs of upper respiratory tract disease and bacterial shedding post infection.
Onset of immunity: 2 weeks.
Duration of immunity: 7 months after primary vaccination.
1 year after revaccination.

None.

Revised: April 2024
AN: 00499/2023

Dogs:
Very common
(> 1 animal / 10 animals
treated):
Injection site swelling 2 cm, occasionally firm,
may be present up to 25 days post-vaccination).

Common
(1 to 10 animals / 100 animals
treated):
Injection site swelling 3.5 cm may be present
up to 25 days post-vaccination
and can be
painful).
Very rare
(< 1 animal / 10,000 animals
treated, including isolated
reports):
Hypersensitivity reaction.
1
The swelling may uncommonly last for up to 35 days post-vaccination.
If hypersensitivity reaction occurs, appropriate treatment should be administered without
delay. Such reactions may evolve to a more severe condition which may be life-threatening.
Reporting adverse events is important. It allows continuous safety monitoring of a
veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to
either the marketing authorisation holder or its local representative or the national
competent authority via the national reporting system. See the package leaflet for
respective contact details.

Vaccinate healthy animals only.

Special precautions for use in animals
Not applicable.
Special precautions to be taken by the person administering the veterinary medicinal
product to animals
Not applicable.
Special precautions for the protection of the environment
Not applicable.
Other precautions
Not applicable.

Safety and efficacy data are available which demonstrate that this vaccine can be
administered at the same time but not mixed with the live vaccines in the Canigen
range against canine distemper, canine contagious hepatitis caused by canine
adenovirus type 1, canine parvovirus disease and respiratory disease caused by
canine adenovirus type 2, where authorised.
Safety data are available which demonstrate that this vaccine can be administered at
the same time but not mixed with the Canigen range of vaccines mentioned above
together with the live Canigen parainfluenza vaccine and the inactivated vaccines in
the Canigen range against leptospirosis caused by L. interrogans serogroup Canicola
serovar Canicola, L. interrogans serogroup Icterohaemorrhagiae serovar
Copenhageni, L. interrogans serogroup Australis serovar Bratislava, and L. kirschneri
serogroup Grippotyphosa serovar Bananal/Lianguang.
In addition, for the live canine parainfluenza vaccine there are antibody response
data, and for the inactivated canine leptospirosis vaccines there are antibody
response data and other immunity data which support the use of the vaccine at the
same time but not mixed with the mentioned Canigen range of vaccines.
When this vaccine is administered in association with the relevant Canigen vaccines,
the demonstrated safety and efficacy claims of the vaccine are the same as when
this vaccine is administered alone.
The product information of the relevant Canigen vaccines used in association with
this vaccine should be consulted before administration.
No information is available on the safety and efficacy of this vaccine when used with
any other veterinary medicinal product except the products mentioned above. A
decision to use this vaccine before or after any other veterinary medicinal product
therefore needs to be made on a case by case basis.

Store in a refrigerator (2 C – 8 C). Do not freeze.
Once broached store between 2 C – 25 C. Do not freeze.
Store in the original package in order to protect from light.

Not applicable.
5. IMMUNOLOGICAL PROPERTIES
Pharmacotherapeutic group: Immunologicals for Canidae, inactivated bacterial
vaccines (including mycoplasma, toxoid and chlamydia)
ATCvet code: QI07AB03.
The subunit vaccine stimulates active immunity against Bordetella bronchiseptica
infection in dogs.

This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.